|Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide|
V Marconi, S Bonhoeffer, R Paredes, J Lu, R Hoh, JN Martin, SG Deeks, ...
Journal of acquired immune deficiency syndromes (1999) 48 (5), 572, 2008
|The potential role of interleukin-2 in patients with HIV infection|
R Paredes, JCLB de Quiros, E Fernández-Cruz, B Clotet, HC Lane
AIDS Rev 4, 36-40, 2002
|Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse …|
SL Pett, J Amin, A Horban, J Andrade-Villanueva, M Losso, N Porteiro, ...
Clinical Infectious Diseases 63 (1), 122-132, 2016
|A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy|
R Paredes, MC Puertas, W Bannister, M Kisic, A Cozzi-Lepri, C Pou, ...
Journal of Infectious Diseases 204 (5), 741-752, 2011
|Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation|
R Paredes, PL Tzou, G Van Zyl, G Barrow, R Camacho, S Carmona, ...
PLoS One 12 (7), e0181357, 2017
|Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants|
M Noguera-Julian, A Cozzi-Lepri, F Di Giallonardo, R Schuurman, ...
Clinical microbiology and infection 22 (2), 191-200, 2016
|Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: the data collection on adverse events of …|
H Kovari, CA Sabin, B Ledergerber, L Ryom, P Reiss, M Law, C Pradier, ...
Open forum infectious diseases 3 (1), 2016
|Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4|
D Nicolás, J Ambrosioni, R Paredes, MÁ Marcos, C Manzardo, A Moreno, ...
Expert review of anti-infective therapy 13 (8), 947-963, 2015
|HIV resistance testing and detected drug resistance in Europe|
A Schultze, AN Phillips, R Paredes, M Battegay, JK Rockstroh, L Machala, ...
Aids 29 (11), 1379-1389, 2015
|Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211|
AMN Tsibris, R Paredes, A Chadburn, Z Su, TJ Henrich, A Krambrink, ...
Clinical infectious diseases 48 (5), 642-649, 2009
|The evolving landscape of HIV drug resistance diagnostics for expanding testing in resource-limited settings|
SC Inzaule, RL Hamers, R Paredes, C Yang, R Schuurman, ...
AIDS Rev 19 (4), 219-230, 2017
|Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy|
WP Bannister, A Cozzi-Lepri, J Kjær, B Clotet, A Lazzarin, JP Viard, ...
Journal of antimicrobial chemotherapy 66 (4), 901-911, 2011
|" Therapy: it's a two-way thing": women survivors of child sexual abuse describe their therapy experiences|
PhD Thesis-University of Auckland, 2003
|Evolution of the gut microbiome following acute HIV-1 infection|
M Rocafort, M Noguera-Julian, J Rivera, L Pastor, Y Guillén, J Langhorst, ...
Microbiome 7 (1), 73, 2019
|Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors|
S Franco, R Bellido, E Aparicio, N Canete, M García‐Retortillo, R Sola, ...
Journal of viral hepatitis 18 (10), e578-e582, 2011
|In–depth characterization of viral isolates from plasma and cells compared with plasma circulating quasispecies in early HIV-1 infection|
J Dalmau, FM Codoñer, I Erkizia, M Pino, C Pou, R Paredes, B Clotet, ...
PloS one 7 (2), e32714, 2012
|Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 …|
E Negredo, R Paredes, A Bonjoch, A Tuldra, CR Fumaz, S Gel, B Garces, ...
Antiviral therapy 4, 23-28, 1999
|Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing|
ER Lee, N Parkin, C Jennings, CJ Brumme, E Enns, M Casadellà, ...
Scientific reports 10 (1), 1-10, 2020
|Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study|
E Negredo, R Paredes, J Peraire, E Pedrol, H Côté, S Gel, CR Fumaz, ...
Antivir Ther 9 (6), 889-93, 2004
|Simplification of antiretroviral treatment from darunavir/ritonavir monotherapy to darunavir/cobicistat monotherapy: effectiveness and safety in routine clinical practice|
JR Santos, A Curran, J Navarro-Mercade, MF Ampuero, P Pelaez, ...
AIDS research and human retroviruses 35 (6), 513-518, 2019